Cardiology

In a presentation at the annual HFSA meeting, investigators compare the level of care and ultimate outcomes treating heart failure patients for cardiologists and non-cardiologists.

As safety and efficacy programs advance, clinicians consider the investigative therapy's potential in cardiology.

At the annual HFSA meeting, investigators explain how obstructed sleep apnea and central sleep apnea drive cardiovascular disease.

A new study shows just more than 55% of all heart failure-based trials on ClinicalTrials.gov have shared results since 2008.

Investigators report findings no significant associations between BP control and cardiovascular mortality in patients from differing race/ethnicities with HF, stratified by hypertension treatment.

A post hoc analysis of TOPCAT shows older patients with HFpEF report consistent efficacy with spironolactone, but worsening safety outcomes.

Lab tests confirm low levels of NDMA in the popular heart burn medication, sparking a probe in the US and Europe.

Prior to the start of HFSA, Dr. Murray dives through how the extensive history of heart failure research has lead to today's greatest cardiovascular breakthroughs.

A recent analysis that included data on 284 patients found that more than 80% of patients with resistant hypertension also had obstructive sleep apnea.

Through clinical trials, investigators find that SGLT2 inhibitors are not only safe, but have several cardiovascular benefits.

The scope and scale of kidney disease is on the rise—much like its most commonly associated conditions.

A recent study found the lifetime risk of peripheral artery disease in black patients was around 30% while Hispanic and white patients had prevalence rates around 20%.

A recent study from investigators at the Rutgers Robert Wood Medical School found that rates of hypertension among pregnant women have spiked between 1970 and 2010.

A study from the University of California San Francisco found that patients with HIV were at an 80% increased risk of suffering from atrial fibrillation.

Dhruv Kazi, MD, of Beth Israel Deaconess Medical Center, discusses a recent study he led into the cost-effectiveness of polypill and why we do not see the approach applied to cardiovascular disease in the US.

Suraj Kapa, MD, takes part in an episode of DocTalk where he discusses the results of a recent study he led and how to implement technology into cardiology in a way that benefits patients and physicians.

The inaugural episode of the DocTalk Podcast features a conversation about transcatheter aortic valve replacement with two cardiologists from Brigham and Women's Hospital.

A study from investigators at Beth Israel Deaconess Medical Center found that more intense hypertensive treatments did not result in added episodes of orthostatic hypotension.

A study from the AHA's Hypertension Scientific Sessions revealed first- and second-year medical students have a 2.4 higher risk of stage 2 hypertension compared to the general public.

A study of human gut bacteria suggests that high blood pressure with depression may be a completely different disease than high blood pressure without depression.

A Q&A with Brett Carroll, MD, director of Vascular Medicine at Beth Israel Deaconess Medical Center, as he discusses stroke management, DOACs, and warfarin.

A study from the AHA's 2019 Hypertension Scientific Sessions revealed that hypertension was linked to cognitive decline in older patients, but antihypertensive treatment could mitigate this impact.

The DocTalk Podcast, a weekly conversation with leaders and experts in medicine, will launch with 3 new episodes on September 9.

Initial PCSK9 inhibitor plus statin therapy helped hospitalized patients achieve LDL-C